Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance

BACKGROUND: Colorectal carcinoma (CRC) is the third most common cancer worldwide. Platinum-based anticancer compounds still constitute one mainstay of systemic CRC treatment despite limitations due to adverse effects and resistance development. Trabectedin has shown promising antitumor effects in CR...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Br J Cancer
Hoofdauteurs: Englinger, B, Mair, M, Miklos, W, Pirker, C, Mohr, T, van Schoonhoven, S, Lötsch, D, Körner, W, Ferk, F, Knasmüller, S, Heffeter, P, Keppler, B K, Grusch, M, Berger, W
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Nature Publishing Group 2017
Onderwerpen:
Translational Therapeutics
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5318979/
https://ncbi.nlm.nih.gov/pubmed/28095394
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.449
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items